%A Wang, Bo 
%A Li, Jian 
%A Zhang, Qianyu 
%A Li, Yuting 
%A Ren, Wu 
%A He, Du 
%D 2024
%T Metformin mitigates cisplatin-induced ovarian damage through inhibiting the pyroptosis of granulosa cells via ROS/TXNIP/NLRP3 signaling pathway
%! Metformin mitigates cisplatin-induced ovarian damage through inhibiting the pyroptosis of granulosa cells via ROS/TXNIP/NLRP3 signaling pathway
%K ovarian damage, cisplatin, metformin, pyroptosis, ROS/TXNIP/NLRP3 pathway
%X Cisplatin, a vital chemotherapy drug for solid malignant tumors, can detrimentally affect ovarian health and fertility in premenopausal patients with cancer. Currently, effective strategies to mitigate cisplatin-induced ovarian damage remain limited. Several studies have highlighted the potential of metformin as an anticancer agent with anti-aging properties and other health benefits. Hence, the present study established an animal model to investigate the impact of metformin on cisplatin-induced ovarian damage, elucidating its mechanisms using bulk RNA sequencing analysis and Western blotting. Our study findings demonstrate that metformin significantly prevents the decline in cisplatin-induced ovarian reserve, maintaining anti-müllerian hormone (AMH) and estradiol (E2) levels. Moreover, metformin may effectively improve cisplatin-induced ovarian fibrosis and granulosa cell pyroptosis through the ROS/TXNIP/NLRP3 pathway. In summary, our study indicates that metformin holds promise in alleviating cisplatin-induced ovarian damage, offering a potential avenue to preserve female fertility during chemotherapy.
%U https://doi.org/10.18632/aging.205659
%J Aging
%0 Journal Article
%R 10.18632/aging.205659
%@ 1945-4589